Suppr超能文献

10q 状态在基于结果的 1p/19q 荧光原位杂交和聚合酶链反应微卫星杂合性丢失分析的少突胶质细胞瘤之间的比较中的重要性。

The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas.

机构信息

Department of Pathology, University of Kentucky, Lexington, Kentucky, USA.

出版信息

J Neuropathol Exp Neurol. 2012 Jan;71(1):73-82. doi: 10.1097/NEN.0b013e318240fa65.

Abstract

1p/19q codeletion is a favorable prognostic marker of oligodendrogliomas. Although fluorescence in situ hybridization (FISH) and microsatellite-based polymerase chain reaction (PCR) for loss of heterozygosity (LOH) are common methods to test for 1p/19q codeletion, it is unclear which test is better at prognostic stratification. This study analyzed outcomes of 111 oligodendrogliomas with both 1p/19q FISH and LOH done at the time of diagnosis. Overall concordance between the 2 assays was 81.1%. In grade III oligodendrogliomas, LOH was better than FISH at survival stratification (p < 0.0001 for LOH vs p = 0.02 for FISH), although increasing the stringency of FISH interpretation criteria improved concordance and prognostic power. Oligodendrogliomas that were 1p/19q-codeleted by FISH but also had 10q LOH were negative for 1p/19q codeletion by PCR analysis in more than 70% of cases, with very poor survival in the grade III subset. Thus, although PCR-based LOH is a better stratifier of 1p/19q status, FISH still has clinical and prognostic utility, especially if 10q data can be incorporated.

摘要

1p/19q 缺失是少突胶质细胞瘤的有利预后标志物。荧光原位杂交(FISH)和基于微卫星的聚合酶链反应(PCR)检测杂合性丢失(LOH)是检测 1p/19q 缺失的常用方法,但哪种方法更适合预后分层尚不清楚。本研究分析了 111 例同时进行 1p/19q FISH 和 LOH 检测的少突胶质细胞瘤的结果。两种检测方法的总体一致性为 81.1%。在 III 级少突胶质细胞瘤中,LOH 在生存分层方面优于 FISH(LOH 优于 FISH,p < 0.0001,而 FISH 优于 FISH,p = 0.02),尽管增加 FISH 解释标准的严格性可以提高一致性和预测能力。通过 FISH 检测到的 1p/19q 缺失但也存在 10q LOH 的少突胶质细胞瘤,在超过 70%的病例中通过 PCR 分析为 1p/19q 缺失阴性,III 级亚组的生存率非常差。因此,尽管基于 PCR 的 LOH 是 1p/19q 状态更好的分层因素,但 FISH 仍然具有临床和预后价值,尤其是如果可以纳入 10q 数据。

相似文献

4
Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas?1p/19q 缺失是否为少突胶质细胞瘤的诊断标志物?
Cancer Genet Cytogenet. 2009 Oct;194(1):12-22. doi: 10.1016/j.cancergencyto.2009.05.004.

引用本文的文献

5
Neuro-Oncology and Radiogenomics: Time to Integrate?神经肿瘤学与放射基因组学:是时候整合了吗?
AJNR Am J Neuroradiol. 2020 Nov;41(11):1982-1988. doi: 10.3174/ajnr.A6769. Epub 2020 Sep 10.
9
1p/19q codeletion and RET rearrangements in small-cell lung cancer.小细胞肺癌中的1p/19q共缺失和RET重排
Onco Targets Ther. 2016 Jun 16;9:3571-7. doi: 10.2147/OTT.S108781. eCollection 2016.

本文引用的文献

1
EGFR expression stratifies oligodendroglioma behavior.EGFR 表达分层少突胶质瘤行为。
Am J Pathol. 2011 Oct;179(4):1638-44. doi: 10.1016/j.ajpath.2011.06.020. Epub 2011 Aug 11.
9
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.所有 1p19q 共缺失型神经胶质瘤均存在 IDH1 或 IDH2 突变。
Neurology. 2010 Jun 8;74(23):1886-90. doi: 10.1212/WNL.0b013e3181e1cf3a. Epub 2010 Apr 28.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验